Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Description

This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.

Conditions

Smoking Cessation

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Condition
Smoking Cessation
Intervention / Treatment

-

Contacts and Locations

Kansas City

University of Kansas Medical Center, Kansas City, Missouri, United States, 64130

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * African American
  • * age \>18 years
  • * interested in quitting
  • * smoked \>1 cpd for \>1 years
  • * smoked on \>25 days in the past month
  • * willing to take 6 months of study medication and complete all visits
  • * have a home address and functioning telephone number
  • * Consistent with contraindications for bupropion:
  • * use of psychoactive medications
  • * history of alcohol or substance abuse within the past year
  • * binge drinking (\>5 drinks on one occasion) \>2 times in the past month
  • * history of seizures or head trauma; history of bulimia or anorexia nervosa
  • * pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding
  • * myocardial infarction in the past 2 months
  • * reported use of opiates, cocaine, or stimulants
  • * unstable diabetes
  • * bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded.
  • * use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days
  • * planning to move from the Kansas City area in the next year
  • * other smoker in household enrolled in the study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Kansas Medical Center,

Lisa Sanderson Cox, PhD, PRINCIPAL_INVESTIGATOR, University of Kanas Medical Center

Study Record Dates

2026-07-30